MK-677 vs CJC-1295 + Ipamorelin
MK-677 and the CJC-1295 + ipamorelin stack are the two most popular approaches to growth hormone optimization — but they differ fundamentally in administration (oral vs injectable), mechanism, selectivity, and side effect profile. This comparison helps clarify which approach might be more appropriate for different goals.
The choice between MK-677 (oral pill) and CJC-1295 + Ipamorelin (injectable stack) is really a choice between convenience and clean mechanism. MK-677 wins on ease of use — one daily pill. But it stimulates appetite significantly, may worsen insulin sensitivity, and produces sustained (not pulsatile) GH. The injectable stack is cleaner metabolically but requires daily needles. Most people who prioritize body composition end up on the injectables.
MK-677
An orally active growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release.
CJC-1295
A growth hormone-releasing hormone analog that stimulates the pituitary gland to produce more growth hormone.
Ipamorelin
A selective growth hormone secretagogue that, in animal studies, released GH without the ACTH and cortisol rise seen with older GHRPs.
| Category | MK-677 | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Administration | Oral (capsule/liquid) — daily | Subcutaneous injection — daily or several times per week | Subcutaneous injection — daily |
| Mechanism | Non-peptide ghrelin receptor agonist (GHS-R1a) | GHRH receptor agonist (extends natural GHRH signal) | Selective ghrelin receptor agonist (GHS-R1a) |
| GH Release Pattern | Sustained elevation over 24 hours (less pulsatile) | Amplifies natural GH pulse amplitude | Triggers discrete GH pulses |
| Appetite Effects | Significant appetite increase (common complaint) | No significant appetite change | Minimal appetite change (highly selective) |
| Cortisol Effects | May increase cortisol modestly | No significant cortisol change | No cortisol or prolactin increase |
| Insulin Sensitivity | May worsen insulin sensitivity with prolonged use | Neutral to minimal impact | Neutral |
| Evidence Level | Moderate — multiple human trials, not FDA-approved | Moderate — Phase I/II human data | Moderate — human pharmacodynamic studies |
| Convenience | High — simple daily oral dose | Lower — requires injection | Lower — requires injection |
| FDA Compounding Status | Still in FDA compounding Category 2 (significant safety risks) for both 503A pharmacies and 503B outsourcing facilities | Withdrawn from Category 2 in April 2026, but on no 503A bulks list — not an authorization to compound | Withdrawn from 503A Category 2 in April 2026 (still Category 2 for 503B); on no 503A bulks list |
In depth
Oral vs injectable is the surface difference
The first thing you notice about this comparison is the route: MK-677 is an oral capsule or liquid (one dose daily), while CJC-1295 + Ipamorelin is a subcutaneous injection (the stack is typically daily before bed). For a lot of people, that's enough to decide — oral is so much easier to sustain over months that the other differences matter less. But the pharmacology differences below the route are substantial and worth understanding before defaulting to MK-677 on convenience alone.
Mechanism and GH pattern
MK-677 is a non-peptide ghrelin receptor agonist — a small molecule that binds the same receptor Ipamorelin does, just orally bioavailable with a 24-hour half-life. That long half-life produces sustained GH/IGF-1 elevation over the full day, which sounds good but departs from the natural pulsatile pattern of endogenous GH release. The CJC-1295 + Ipamorelin stack works differently: CJC-1295 amplifies GHRH-receptor signaling, Ipamorelin triggers ghrelin-receptor GH pulses, and the combination produces synergistic but still relatively pulsatile GH release. Whether pulsatile matters clinically is debated, but many endocrinologists consider physiologic GH patterning to be meaningful for receptor sensitivity and downstream IGF-1 dynamics over time.
Selectivity and side effects
This is where the comparison gets interesting for body composition goals. MK-677's biggest real-world drawback is appetite stimulation — sometimes substantially so. The ghrelin-receptor mechanism it hits is the same one that signals hunger, and the sustained elevation means sustained appetite drive. For users trying to lose or maintain weight, this can be counterproductive enough to negate the drug's other benefits. MK-677 also has modest negative impacts on insulin sensitivity over prolonged use and mild cortisol elevation in some studies. Ipamorelin, by contrast, is the "clean" ghrelin-mimetic — in animal studies it raised GH without raising ACTH or cortisol, and appetite effects are typically milder than MK-677's sustained drive, though some hunger is still reported. CJC-1295 is similarly clean.
Convenience
MK-677 is the clear winner. It's oral (no injection skill required) and once-daily. The injectable stack requires daily subcutaneous injections and dual peptide supply (or a pre-mixed combination). For users whose compliance with injectable therapy would be poor, MK-677's ease of use often matters more than any other consideration.
Bottom line
If convenience is the deciding factor and you're not primarily focused on body composition, MK-677 is a reasonable choice that delivers real IGF-1 elevation with minimal friction. If you're optimizing body composition — losing fat, gaining lean mass — MK-677's appetite stimulation can work against you, and the CJC-1295 + Ipamorelin stack has a cleaner metabolic profile. If you care about physiologic GH patterning or have any insulin sensitivity concern, the injectable stack is the more conservative choice. Many clinicians start patients on MK-677 for simplicity and transition to the injectable stack if appetite or blood sugar becomes problematic. Both approaches require monitoring; neither is a substitute for the sleep, training, and nutrition inputs that drive endogenous GH rhythm.
These peptides are often used together. See our stack profiles for combination details.